News News

January 5, 2015 Sirnaomics and Partner Submit IND to CFDA

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration (CFDA) for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

Sirnaomics News Placeholder 02
July 8, 2014 Sirnaomics Strengthens Its IP Position for Advancing the Company’s Novel siRNA Therapeutics Programs

Sirnaomics announced today that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled “Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin” (US 8,735,567 B2, PCT/US2008/012498).

Sirnaomics Dr. Patrick Lu
June 25, 2014 Dr. Patrick Lu Speaks in “The European Summit for Clinical Nanomedicine and Targeted Medicine”

This is an annual conference organized by European Foundation for Clinical Nanomedicine (CLINAM). Dr. Patrick Lu, President and CSO of Sirnaomics, Inc., was invited by the organizing committee to speak in a platinum session “Peptide-Based Nanoparticles for Targeted Delivery of siRNA”.

Sirnaomics News Placeholder 01
December 19, 2012 Sirnaomics Advances Its Novel siRNA Therapeutics Against HPV Infection and Cervical Cancer

Sirnaomics announced today that the company has made a major breakthrough in its novel small interfering RNA (siRNA) therapeutic product against human papillomavirus (HPV) infection and cervical cancer.

Sirnaomics News Placeholder 05
June 28, 2012 Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field

Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China.

Sirnaomics News Placeholder 04
June 25, 2012 Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics

Sirnaomics announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.

1 9 10 11 12